We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rapid Ebolavirus Triage Test Developed

By LabMedica International staff writers
Posted on 25 Feb 2015
A Rapid Ebolavirus Triage Test is designed to enable healthcare workers, even in challenging environments, to test blood samples and aims at providing accurate and fast diagnosis of Ebola. More...
The test is designed to offer a unique combination of speed, sensitivity, accuracy and ease-of-use required for outbreaks where time is of the essence.

The test uses 0.2 mL blood that is added directly to the Idylla cartridge, which contains all necessary reagents on board for performing the analysis on Biocartis (Mechelen, Belgium) fully automated, molecular diagnostics system. A complete analysis of the sample takes around 90 minutes and can be operated by healthcare professional in most settings, including in the field, making the test ideal for use in regions with limited infrastructure.

The Rapid Ebola Virus Triage Test was developed in association with Janssen Diagnostics (Beerse, Belgium) and the Institute for Tropical Medicine (Antwerp, Belgium) for its Idylla system, a fully automated molecular diagnostic platform that is CE-IVD marked in Europe. The company believes its Rapid Ebola Virus Triage Test could provide a sustainable solution for rapid detection of Ebola-infected patients even after the current Ebola outbreak. After testing of synthetic virus samples in Belgium and the USA, Biocartis has now registered for field-testing in West Africa to gather additional clinical evidence for the test performance.

Rudi Pauwels, PhD, Biocartis' Chief Executive Officer commented, “This test aims not only to improve the diagnosis of the Ebola virus for hard-pressed healthcare professionals in the field, but to lay the foundations for a better and faster diagnostic infrastructure after the current outbreak has receded, both in this region and around the world. One of the lessons of the Ebola outbreak has been the urgent need for faster and more accurate diagnostics. Biocartis is pleased to be working, alongside prestigious partners, on what it believes could offer a viable solution for healthcare workers around the world to enable faster testing of infectious diseases in virtually any setting.”

Related Links:

Biocartis
Janssen Diagnostics 
Belgian Institute for Tropical Medicine 



Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
Gold Member
Hematology Analyzer
Medonic M32B
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.